CD44 and cancer: It is also feasible to design signaling perturbation strategies to downregulate the expression of HA/CD44-regulated Nanog/Oct4/Sox2 and c-Jun as well as certain miRNAs (e.g., miR-21, miR-10b, and miR-302) using specific inhibitors such as siRNA and shRNA and anti-miRNA inhibitor approaches to simultaneously suppress both oncogenic behaviors and cancer progression.